That is a strong statement, but the data backs it up
What this really shows though between Eli Lilly, Novo, and other companies that are almost certainly going to get into the GLP-1 business, I think this is going to be like Insulin all over again, where there's just going to be a series of product improvements, and companies will drive innovation and increase supply
Differential pathophysiological mechanisms between CHS and EHS While CHS and EHS share core pathogenic pathways (e.g., hyperthermia, inflammation, cell death), their mechanistic features differ significantly due to distinct patient demographics and triggers: Inflammatory kinetics EHS (predominant in young, active individuals) is characterized by rapid, exertion-amplified inflammatory responses
It can exacerbate sleep apnea and arthritis, and cause pregnancy complications and issues with fertility